Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20554046 | 0.86 | KDM4E (0.43) | RAB9AKDM4EMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL20554915 | 0.86 | KDM4E (0.38) | RAB9AKDM4EMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL30132632 | 0.86 | KDM4E (0.38) | RAB9AKDM4EMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL20554811 | 0.86 | SLC6A4 (0.43) | KDM4EMAPK1GAAMAOAMAOB | |
| SCHEMBL30132678 | 0.86 | SLC6A4 (0.43) | KDM4EMAPK1GAAMAOAMAOB | |
| SCHEMBL20554693 | 0.83 | BRD4 (0.46) | RAB9AKDM4EMAPTMAOAMAOB | |
| SCHEMBL30132681 | 0.80 | RAB9A (0.45) | RAB9AKDM4EMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL20554355 | 0.80 | RAB9A (0.45) | RAB9AKDM4EMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL20554745 | 0.78 | SLC40A1 (0.37) | RAB9AKDM4ESMN1; SMN2GAAMAOA | |
| SCHEMBL30132530 | 0.78 | SLC40A1 (0.37) | RAB9AKDM4ESMN1; SMN2GAAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110770211-B | Alpha, beta unsaturated amide compound | 协和麒麟株式会社 | 2023-09-19 | — | — | CN | disclosed |
| CN-108430972-B | Alpha, beta-unsaturated amide compound | 协和麒麟株式会社 | 2022-12-27 | — | — | CN | disclosed |
| US-11447471-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-09-20 | — | — | US | disclosed |
| US-11332455-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20210380551-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
| US-20210155612-A1 | Alpha,Beta-UNSATURATED AMIDE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2021-05-27 | — | — | US | disclosed |
| US-10787428-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2020-09-29 | — | — | US | disclosed |
| EP-3712129-A1 | ALPHA, BETA-UNSATURATED AMIDE COMPOUND | Kyowa Kirin Co., Ltd. (JP) | 2020-09-23 | — | — | EP | disclosed |
| CN-110770211-A | α unsaturated amide compound | 协和麒麟株式会社 | 2020-02-07 | — | — | CN | disclosed |
| US-20190010136-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-01-10 | — | — | US | disclosed |
| EP-3401309-A1 | a, ß UNSATURATED AMIDE COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155612-A1 | Alpha,Beta-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, RXRA | GRM4 910/4885RAB9A 3402/4885KDM4E 4216/4885 |
| US-11447471-B2 | α,β-unsaturated amide compound | NR1H2, RXRA, RXRB | GRM4 804/4885RAB9A 3497/4885KDM4E 4037/4885 |
| US-10787428-B2 | α,β-unsaturated amide compound | NR1H2, NCOA1, NR0B1 | GRM4 702/4885RAB9A 3435/4885KDM4E 3428/4885 |
| US-20210380551-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, NCOA1 | GRM4 853/4885RAB9A 3287/4885KDM4E 3742/4885 |
| US-11332455-B2 | α,β-unsaturated amide compound | NR1H2, NCOA1, NR0B1 | GRM4 702/4885RAB9A 3435/4885KDM4E 3428/4885 |
| US-20190010136-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, NCOA1 | GRM4 853/4885RAB9A 3287/4885KDM4E 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.